Rhumbline Advisers X4 Pharmaceuticals, Inc Transaction History
Rhumbline Advisers
- $104 Billion
- Q1 2025
A detailed history of Rhumbline Advisers transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Rhumbline Advisers holds 188,415 shares of XFOR stock, worth $37,683. This represents 0.0% of its overall portfolio holdings.
Number of Shares
188,415
Previous 178,725
5.42%
Holding current value
$37,683
Previous $137,000
65.69%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding XFOR
# of Institutions
99Shares Held
99.6MCall Options Held
421KPut Options Held
80.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$3.38 Million3.52% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$3 Million0.82% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$2.14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$1.64 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY7.31MShares$1.46 Million2.9% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $13.7M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...